Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Global licensing deal (excluding North America) with Hyloris Pharmaceuticals with RHB-102 for up to $60 million in potential...
Read More Details
Finally We wish PressBee provided you with enough information of ( RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights )
Also on site :